ウロキナーゼの世界市場レポート 2025年

ウロキナーゼの市場は、心血管疾患の有病率の増加により成長が見込まれています。心血管疾患（CVD）には、心臓発作、脳卒中、高血圧など、心臓や血管に影響を及ぼすさまざまな疾患が含まれます。CVD患者の増加は、座りがちなライフスタイルによる肥満率の上昇、食生活の乱れ、高齢化などの要因に起因しています。ウロキナーゼは、血流を阻害する血栓を溶解することで、心臓発作や脳卒中を予防し、適切な循環を回復させ、心血管系へのさらなるダメージを軽減することで、心血管系疾患による影響の増大に対処します。例えば、2022年8月に米国心臓病学会が発表した報告書では、2025～2060年にかけて米国における主要な心血管危険因子の大幅な増加が予測されています。糖尿病は39.3％増の5,500万人に達すると予想され、脳卒中（33.8％増の1,500万人）、心不全（33.4％増の1,300万人）、虚血性心疾患（30.7％増の2,900万人）、心臓発作（16.9％増の1,600万人）についても大幅な増加が予想されています。このような心血管疾患の負担増が、ウロキナーゼ市場の拡大を牽引しています。

ウロキナーゼ市場の主要プレーヤーは、治療効果、市場競争力、患者アクセスを向上させるため、新たな適応症に対する医薬品の再導入と商品化に注力しています。このプロセスには、以前に販売されていた医薬品や販売中止となった医薬品を新たな用途で再び市場に投入し、マーケティング、流通、販売を成功させるための戦略を実施することが含まれます。例えば、2023年5月、米国のバイオ医薬品会社であるMBX Biosciencesは、同じく米国の製薬会社であるSequel Pharma LLCと共同で、kinlyticウロキナーゼを再導入し、商品化しました。その目的は、カテーテルクリアランス市場におけるプレゼンスを強化し、患者の治療成績を向上させることです。この提携は、戦略的提携を活用して医薬品を復活させ、現代の市場の要求と規制基準を満たすように販売促進を図るという動向を強調するものです。

2023年8月、米国の製薬会社Eli Lilly and CompanyはDICE Therapeutics Inc.を480億米ドルで買収しました。この買収は、Eli Lillyの革新的治療における研究開発能力を強化することを目的としており、ウロキナーゼに基づく治療と交差する可能性のある治療法の開発と最適化を含め、血栓溶解治療および関連分野におけるポートフォリオを前進させる可能性があります。DICE Therapeutics Inc.は米国を拠点とするバイオテクノロジー企業で、自己免疫疾患や炎症性疾患の新規治療薬を専門としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のウロキナーゼ市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のウロキナーゼ市場：成長率分析
• 世界のウロキナーゼ市場の実績：規模と成長、2019～2024年
• 世界のウロキナーゼ市場の予測：規模と成長、2024～2029年、2034年
• 世界のウロキナーゼ総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のウロキナーゼ市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ウロキナーゼパウダー
• ウロキナーゼソリューション
• 世界のウロキナーゼ市場：製造工程別、実績と予測、2019～2024年、2024～2029年、2034年
• バイオテクノロジー的方法
• 伝統的な抽出法
• 世界のウロキナーゼ市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• カテーテルクリアランス
• 冠動脈血栓症
• 深部静脈血栓症
• 肺塞栓症
• 世界のウロキナーゼ市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のウロキナーゼ市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• その他
• 世界のウロキナーゼ市場、ウロキナーゼパウダーのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 医薬品グレードウロキナーゼパウダー
• 研究グレードウロキナーゼパウダー
• 組み換えウロキナーゼパウダー
• 世界のウロキナーゼ市場：ウロキナーゼソリューションのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 注射用ウロキナーゼソリューション
• 注入ウロキナーゼソリューション
• 混合ウロキナーゼソリューション

第7章 地域別・国別分析

• 世界のウロキナーゼ市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のウロキナーゼ市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ウロキナーゼ市場：競合情勢
• ウロキナーゼ市場：企業プロファイル
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Mochida Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Bharat Serums and Vaccines Limited Overview, Products and Services, Strategy and Financial Analysis
  • Taj Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • TTK Health Care Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Agrata Biotech Limited
• Cerbios-Pharma SA
• Microbix Biosystems Inc.
• Midas Pharma GmbH
• ImaRx Therapeutics
• Health Biotech Limited
• Salvavidas Pharmaceutical Pvt. Ltd.
• BBT Biotech GmbH
• Syner-Med（Pharmaceutical Products）Ltd.
• Echelon Biosciences Inc.
• Kraeber & Co GmbH
• Samarth Life Science Pvt. Ltd.
• WUHAN HANWEISHI PHARMCHEM CO. LTD.
• Aetos Pharma
• MITS CRITICAL CARE

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ウロキナーゼ市場2029：新たな機会を提供する国
• ウロキナーゼ市場2029：新たな機会を提供するセグメント
• ウロキナーゼ市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Urokinase is a therapeutic enzyme used as a thrombolytic agent to dissolve blood clots. It functions by converting plasminogen into plasmin, which then breaks down fibrin, the main protein in blood clots. This treatment is employed in clinical settings to manage conditions like acute myocardial infarction and other blood clot-related disorders by restoring blood flow and minimizing the risk of severe complications from clot formation.

The primary forms of urokinase are urokinase powder and urokinase solution. Urokinase powder is the dry form of the enzyme, which is usually reconstituted with sterile water or saline before use. This powder form facilitates easier storage, transportation, and dosage preparation compared to liquid formulations. The production of urokinase involves both biotechnological methods and traditional extraction processes. It is used for various indications such as catheter clearance, coronary artery thrombosis, deep vein thrombosis, and pulmonary embolism. Urokinase is distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used in different settings like hospitals, clinics, and other medical facilities.

The urokinase market research report is one of a series of new reports from The Business Research Company that provides urokinase market statistics, including urokinase industry global market size, regional shares, competitors with a urokinase market share, detailed urokinase market segments, market trends and opportunities, and any further data you may need to thrive in the urokinase industry. This urokinase market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The urokinase market size has grown strongly in recent years. It will grow from $1.7 $ billion in 2024 to $1.81 $ billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to the increasing incidence of stroke and heart attacks, growth in clinical research, regulatory approvals for critical indications, development of initial formulations, and growing healthcare infrastructure.

The urokinase market size is expected to see strong growth in the next few years. It will grow to $2.26 $ billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to a growing focus on personalized medicine, increasing prevalence of pulmonary embolism, growing investment in cardiovascular and stroke research, increase in diagnostic and imaging techniques, rise in geriatric population, and rising incidence of obesity. Major trends in the forecast period include advancements in personalized medicine, technological innovations in drug delivery systems, integration of AI and digital health tools, advancements in digital health platforms, and development in clinical research.

The urokinase market is expected to grow due to the increasing prevalence of cardiovascular diseases. Cardiovascular diseases (CVDs) encompass a range of conditions affecting the heart and blood vessels, including heart attacks, strokes, and hypertension. The rise in CVD cases is attributed to factors such as higher obesity rates from sedentary lifestyles, poor dietary habits, and an aging population. Urokinase helps address the growing impact of cardiovascular diseases by dissolving blood clots that obstruct blood flow, thereby preventing heart attacks and strokes, restoring proper circulation, and reducing further cardiovascular damage. For instance, a report from the American College of Cardiology in August 2022 projected significant increases in major cardiovascular risk factors in the United States from 2025 to 2060. Diabetes is expected to rise by 39.3% to 55 million individuals, with substantial increases also anticipated for stroke (33.8% to 15 million), heart failure (33.4% to 13 million), ischemic heart disease (30.7% to 29 million), and heart attacks (16.9% to 16 million). This growing burden of cardiovascular diseases is driving the expansion of the urokinase market.

Key players in the urokinase market are focusing on reintroducing and commercializing pharmaceutical products for new indications to improve treatment effectiveness, market competitiveness, and patient access. This process involves bringing previously available or discontinued drugs back to the market for new uses and implementing strategies for successful marketing, distribution, and sales. For example, in May 2023, MBX Biosciences, a US-based biopharmaceutical company, collaborated with Sequel Pharma LLC, another US-based pharmaceutical firm, to reintroduce and commercialize kinlytic urokinase. The goal is to strengthen its presence in the catheter clearance market and enhance patient treatment outcomes. This partnership underscores the trend of leveraging strategic collaborations to revive and promote pharmaceutical products, ensuring they meet contemporary market demands and regulatory standards.

In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired DICE Therapeutics Inc. for $48 billion. This acquisition is intended to enhance Eli Lilly's research and development capabilities in innovative therapies, potentially advancing their portfolio in thrombolytic treatments and related fields, including the development and optimization of therapies that could intersect with urokinase-based treatments. DICE Therapeutics Inc. is a US-based biotechnology company specializing in novel therapies for autoimmune and inflammatory diseases.

Major companies operating in the urokinase market are Thermo Fisher Scientific Inc., Mochida Pharmaceutical Co. Ltd., Bharat Serums and Vaccines Limited, Taj Pharmaceuticals Ltd., TTK Health Care Limited, Agrata Biotech Limited, Cerbios-Pharma SA, Microbix Biosystems Inc., Midas Pharma GmbH, ImaRx Therapeutics, Health Biotech Limited, Salvavidas Pharmaceutical Pvt. Ltd., BBT Biotech GmbH, Syner-Med (Pharmaceutical Products) Ltd., Echelon Biosciences Inc., Kraeber & Co GmbH, Samarth Life Science Pvt. Ltd., WUHAN HANWEISHI PHARMCHEM CO. LTD., Aetos Pharma, MITS CRITICAL CARE

North America was the largest region in the urokinase market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urokinase market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the urokinase market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urokinase market consists of sales of urokinase thrombolytic agents, urokinase enzymes, and urokinase injections. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Urokinase Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urokinase market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urokinase ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urokinase market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Urokinase Powder; Urokinase Solution
• 2) By Manufacturing Process: Biotechnological Methods; Traditional Extraction
• 3) By Indication: Catheter Clearance; Coronary Artery Thrombosis; Deep Vein Thrombosis; Pulmonary Embolism
• 4) By Distribution channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By Application: Hospital; Clinics; Other Applications
• Subsegments:
• 1) By Urokinase Powder: Pharmaceutical-Grade Urokinase Powder; Research-Grade Urokinase Powder; Recombinant Urokinase Powder
• 2) By Urokinase Solution: Injectable Urokinase Solution; Infusion Urokinase Solution; Pre-mixed Urokinase Solution
• Companies Mentioned: Thermo Fisher Scientific Inc.; Mochida Pharmaceutical Co. Ltd.; Bharat Serums and Vaccines Limited; Taj Pharmaceuticals Ltd.; TTK Health Care Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Urokinase Market Characteristics

3. Urokinase Market Trends And Strategies

4. Urokinase Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Urokinase Growth Analysis And Strategic Analysis Framework

• 5.1. Global Urokinase PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Urokinase Market Growth Rate Analysis
• 5.4. Global Urokinase Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Urokinase Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Urokinase Total Addressable Market (TAM)

6. Urokinase Market Segmentation

• 6.1. Global Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urokinase Powder
• Urokinase Solution
• 6.2. Global Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biotechnological Methods
• Traditional Extraction
• 6.3. Global Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Catheter Clearance
• Coronary Artery Thrombosis
• Deep Vein Thrombosis
• Pulmonary Embolism
• 6.4. Global Urokinase Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Urokinase Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinics
• Other Applications
• 6.6. Global Urokinase Market, Sub-Segmentation Of Urokinase Powder, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical-Grade Urokinase Powder
• Research-Grade Urokinase Powder
• Recombinant Urokinase Powder
• 6.7. Global Urokinase Market, Sub-Segmentation Of Urokinase Solution, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Urokinase Solution
• Infusion Urokinase Solution
• Pre-mixed Urokinase Solution

7. Urokinase Market Regional And Country Analysis

• 7.1. Global Urokinase Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Urokinase Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Urokinase Market

• 8.1. Asia-Pacific Urokinase Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Urokinase Market

• 9.1. China Urokinase Market Overview
• 9.2. China Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Urokinase Market

• 10.1. India Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Urokinase Market

• 11.1. Japan Urokinase Market Overview
• 11.2. Japan Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Urokinase Market

• 12.1. Australia Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Urokinase Market

• 13.1. Indonesia Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Urokinase Market

• 14.1. South Korea Urokinase Market Overview
• 14.2. South Korea Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Urokinase Market

• 15.1. Western Europe Urokinase Market Overview
• 15.2. Western Europe Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Urokinase Market

• 16.1. UK Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Urokinase Market

• 17.1. Germany Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Urokinase Market

• 18.1. France Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Urokinase Market

• 19.1. Italy Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Urokinase Market

• 20.1. Spain Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Urokinase Market

• 21.1. Eastern Europe Urokinase Market Overview
• 21.2. Eastern Europe Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Urokinase Market

• 22.1. Russia Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Urokinase Market

• 23.1. North America Urokinase Market Overview
• 23.2. North America Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Urokinase Market

• 24.1. USA Urokinase Market Overview
• 24.2. USA Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Urokinase Market

• 25.1. Canada Urokinase Market Overview
• 25.2. Canada Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Urokinase Market

• 26.1. South America Urokinase Market Overview
• 26.2. South America Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Urokinase Market

• 27.1. Brazil Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Urokinase Market

• 28.1. Middle East Urokinase Market Overview
• 28.2. Middle East Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Urokinase Market

• 29.1. Africa Urokinase Market Overview
• 29.2. Africa Urokinase Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Urokinase Market, Segmentation By Manufacturing Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Urokinase Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Urokinase Market Competitive Landscape And Company Profiles

• 30.1. Urokinase Market Competitive Landscape
• 30.2. Urokinase Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Mochida Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bharat Serums and Vaccines Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Taj Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. TTK Health Care Limited Overview, Products and Services, Strategy and Financial Analysis

31. Urokinase Market Other Major And Innovative Companies

• 31.1. Agrata Biotech Limited
• 31.2. Cerbios-Pharma SA
• 31.3. Microbix Biosystems Inc.
• 31.4. Midas Pharma GmbH
• 31.5. ImaRx Therapeutics
• 31.6. Health Biotech Limited
• 31.7. Salvavidas Pharmaceutical Pvt. Ltd.
• 31.8. BBT Biotech GmbH
• 31.9. Syner-Med (Pharmaceutical Products) Ltd.
• 31.10. Echelon Biosciences Inc.
• 31.11. Kraeber & Co GmbH
• 31.12. Samarth Life Science Pvt. Ltd.
• 31.13. WUHAN HANWEISHI PHARMCHEM CO. LTD.
• 31.14. Aetos Pharma
• 31.15. MITS CRITICAL CARE

32. Global Urokinase Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Urokinase Market

34. Recent Developments In The Urokinase Market

35. Urokinase Market High Potential Countries, Segments and Strategies

• 35.1 Urokinase Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Urokinase Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Urokinase Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer